Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.
Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed. Using bulk population sequencing and a sensitive limiting dilution analysis, the selection of K65R or other resistance mutations did not occur in HIV, suggesting that adefovir can be confidently used as hepatitis B virus (HBV) therapy in HIV/HBV-co-infected patients who do not require antiretroviral therapy.
Sheldon
Julie A
JA
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Corral
Angélica
A
Rodés
Berta
B
Mauss
Stefan
S
Rockstroh
Juergen
J
Berger
Florian
F
Schwarze-Zander
Carolynne
C
Soriano
Vincent
V
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D005814:Genes, Viral / Q000235:genetics; D005838:Genotype; D015658:HIV Infections / Q000150:complications / Q000235:genetics*; D006513:Hepatitis B e Antigens / Q000032:analysis; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods
D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D063065:Organophosphonates; D012367:RNA, Viral; C053001:adefovir; D000225:Adenine